Latest Commercialisation Strategy News

Page 1 of 17
Nanosonics has secured a second US FDA 510(k) clearance for its CORIS System, expanding the range of colonoscopes and gastroscopes eligible for reprocessing. The regulatory milestone supports planned US launch activities, although the company has not disclosed a launch date or financial forecast.
Ada Torres
Ada Torres
11 Nov 2026
EVE Health has signed a binding agreement giving it a 75% share of distributable profit from compounded men’s sexual health products in Australia. The capital-light arrangement preserves EVE’s intellectual property ownership, but provides no minimum volumes or guaranteed revenue.
Victor Sage
Victor Sage
10 Nov 2026
Biotron CEO and executive director Glenn Gilbert has started more than two months ahead of schedule, immediately taking charge of a strategic review centred on SedRx. The review will also test development priorities, capital allocation and partnering options across the company’s drug portfolio.
Ada Torres
Ada Torres
9 Nov 2026
Algorae has secured exclusive Australian commercial rights across eight Umedica-branded molecules while separately advancing a Umedica-supplied product towards regulatory approval. The broader arrangement remains partly non-binding, with financial terms undisclosed and TGA approval still pending.
Victor Sage
Victor Sage
19 Oct 2026
ABx Group has locked in approximately $4.1 million through a placement and fully underwritten share purchase plan, with strategic partner Good Importing International committing $1 million. The funding will support the Deep Leads rare earths project and construction and commissioning of the ALCORE pilot plant, but comes with substantial new equity and options.
Victor Sage
Victor Sage
17 Sept 2026
InFocus Group Holdings has secured $450,000 in a placement to fund the commercialisation of its AI-driven Codexa sweepstakes casino platform, targeting the US market with new compliance technology and patent applications.
Sophie Babbage
Sophie Babbage
3 Sept 2026
Hydrix is ramping up its defence technology efforts, focusing on sensing and autonomous systems aligned with Australia’s $425 billion 2026 National Defence Strategy. The company is developing internal prototypes and forging partnerships to commercialise intellectual property in counter-drone and ISR applications.
Sophie Babbage
Sophie Babbage
31 Aug 2026
Omega Oil & Gas has unveiled exceptionally strong results from its Canyon-3 well, revealing a thick, high-quality oil and gas-bearing Permian interval that significantly expands the scale of its resource base in Queensland’s Taroom Trough.
Maxwell Dee
Maxwell Dee
24 Aug 2026
Dimerix has received a US$10 million upfront payment from Everest Medicines under a regional licensing deal for DMX-200 targeting FSGS in Greater China, South Korea and Southeast Asia. This deal marks Dimerix’s fifth commercial partnership for DMX-200, collectively worth up to A$1.9 billion in milestones and royalties.
Ada Torres
Ada Torres
20 Aug 2026
Proteomics International has achieved a key patent acceptance in Australia for its PromarkerEndo blood test, reinforcing its intellectual property portfolio and commercialisation strategy in a major healthcare market.
Ada Torres
Ada Torres
13 Aug 2026
InFocus Group Holdings has rolled out a major upgrade to its Codexa sweepstakes casino platform, introducing a VIP-style player experience and a proprietary AI-driven compliance engine designed to streamline operations and reduce costs for white-label operators.
Sophie Babbage
Sophie Babbage
12 Aug 2026
Iondrive Limited has independently confirmed strong rare earth recoveries from U.S. magnet waste and gained Oklahoma government support for its first commercial processing module, advancing its U.S. commercialisation strategy.
Maxwell Dee
Maxwell Dee
31 July 2026

Browse the archive

Full archive